<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Moberg Pharma Ab — News on 6ix</title>
    <link>https://6ix.com/company/moberg-pharma-ab</link>
    <description>Latest news and press releases for Moberg Pharma Ab on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 05 Nov 2025 08:01:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/moberg-pharma-ab" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d56cc2beedb30cb6f839e7.webp</url>
      <title>Moberg Pharma Ab</title>
      <link>https://6ix.com/company/moberg-pharma-ab</link>
    </image>
    <item>
      <title>Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential</title>
      <link>https://6ix.com/company/moberg-pharma-ab/news/moberg-pharma-and-karo-healthcare-enter-into-an-exclusive-license-agreement-for-mob-015terclara-in-europe-expanding-access-and-growth-potential</link>
      <guid isPermaLink="true">https://6ix.com/company/moberg-pharma-ab/news/moberg-pharma-and-karo-healthcare-enter-into-an-exclusive-license-agreement-for-mob-015terclara-in-europe-expanding-access-and-growth-potential</guid>
      <pubDate>Wed, 05 Nov 2025 08:01:00 GMT</pubDate>
      <description>Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®.</description>
    </item>
    <item>
      <title>Karo Healthcare enters an exclusive license agreement with Moberg Pharma for MOB-015 in Europe</title>
      <link>https://6ix.com/company/moberg-pharma-ab/news/karo-healthcare-enters-an-exclusive-license-agreement-with-moberg-pharma-for-mob-015-in-europe</link>
      <guid isPermaLink="true">https://6ix.com/company/moberg-pharma-ab/news/karo-healthcare-enters-an-exclusive-license-agreement-with-moberg-pharma-for-mob-015-in-europe</guid>
      <pubDate>Wed, 05 Nov 2025 07:49:00 GMT</pubDate>
      <description>Karo Healthcare AB (&quot;Karo&quot;) has entered an exclusive licensing agreement with Moberg Pharma AB (&quot;Moberg Pharma&quot;) regarding the commercialisation of MOB-015 in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key European markets under the leading global antifungal brand Lamisil®1.</description>
    </item>
  </channel>
</rss>